Cardiovascular Systems Inc
Total Consideration
$851.0M
Share price: $20.00
Purchase-Price Allocation
Goodwill
$369.0M
Intangibles
$15.0M
ABBOTT LABORATORIES — Key Metrics
3 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
M-Score (Beneish; >-1.78 flags risk)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$4
Book Value Per Share
$30
Free Cash Flow Per Share
$4
Cash Per Share
$5
Revenue Per Share
$25
OCF Per Share
$5
Return on Equity
13.1%
Return on Assets
7.8%
Return on Invested Capital
10.0%
Debt to Equity
0.19
Current Ratio
1.58
Quick Ratio
1.18
Asset Turnover
0.53
Days Sales Outstanding
65.29
Days Inventory On Hand
122.58
R&D / Revenue
6.6%
SBC / Revenue
1.5%
Capex / Revenue
4.9%
Working Capital
$9.50B
Net Current Asset Value
$26.00B
Invested Capital
$62.03B
OCF / Net Income
1.47
FCF / Net Income
1.13
Accruals Ratio (Sloan)
-3.5%
Net Debt
$957M
Net Debt / EBITDA
0.10
Interest Coverage
16.33
Cash Coverage
19.40
Dividend Coverage
2.32
Capex Coverage
4.41
Tangible Common Equity
$22.57B
TCE / Total Assets
26.0%
Goodwill / Total Assets
27.7%
NOPAT
$6.21B
Cash ROIC
11.9%
WC / Revenue
21.4%
Capex / D&A
1.51
Reinvestment Rate
9.2%
Total Payout Ratio
76.8%
Asset Growth vs Revenue Growth
0.8%
Revenue 5Y CAGR
5.1%
EPS 5Y CAGR
7.7%
FCF 5Y CAGR
5.3%
EBITDA 5Y CAGR
7.7%
Book Value 5Y CAGR
9.7%
Stock Price (FY-end)
$124
Market Cap
$216.54B
P/E Ratio
33.19
P/S Ratio
4.89
P/B Ratio
4.15
P/TB Ratio
9.59
P/OCF Ratio
22.64
P/FCF Ratio
29.28
Enterprise Value
$217.50B
EV / EBITDA
22.93
EV / Sales
4.91
EV / FCF
29.41
FCF Yield
3.4%
Dividend Yield
1.9%
Shareholder Yield
2.0%
Buyback Yield
0.4%
R&D Yield
1.4%
Capex Yield
1.0%
Dividend Per Share
$2
DPS YoY Growth
7.3%
Operating Leverage
3.17
Graham Number
$50
Shares Variation (YoY)
-6.4%
Beta (5Y)
0.55
Cost of Equity
7.2%
Cost of Debt (after tax)
3.8%
WACC
8.0%
ROIC - WACC Spread
3.9%
52W High
$137
52W Low
$108
Trailing Return 1Y
11.0%
Trailing Return 5Y
27.6%
F-Score (Piotroski)
6.00
M-Score (Beneish)
-2.44
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Beat / Miss vs Estimate
Stock Price on Earnings Dates
ABBOTT LABORATORIES — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.50% | 0.40% | 0.70% | 0.50% | 0.30% | — |
| Foreign Rate Differential | -3.30% | -3.90% | -2.50% | -3.60% | -1.80% | — |
| Other Adjustments | 0.20% | 0.50% | 0.50% | 0.00% | -0.10% | -1.70% |
| R&D Tax Credits | 1.00% | 0.60% | 0.90% | 1.10% | 1.00% | — |
| FDII Deduction | — | 1.10% | 2.00% | 2.20% | 2.30% | 1.70% |
| SBC (Nondeductible) | -1.90% | -1.70% | -0.50% | -0.30% | -0.70% | — |
| Valuation Allowance Change | — | — | 0.00% | 0.00% | -107.10% | — |
| Effective Tax Rate | 10.00% | 13.90% | 16.50% | 14.10% | -91.10% | 22.90% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $497.0M | $1.14B | $1.37B | $941.0M | −$6.39B | $1.94B |
| Income Taxes Paid (Cash) | $970.0M | $1.94B | $1.86B | $1.48B | $1.72B | $1.93B |
ABBOTT LABORATORIES — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Exact Sciences Corporation
Share price: $105.00
ABBOTT LABORATORIES — Litigation CasesNEW
Per-case litigation disclosures sourced from us-gaap:LossContingenciesByNatureOfContingencyAxis dimensional XBRL. Coverage is sparse — most filers aggregate at the parent level (JNJ talc, PFE opioid) — but high-value when per-case disclosure exists. Loss estimate is either a single point or a low/high range, depending on how the issuer values the contingency.
As of 2025-12-31
| Case | Estimated Loss | Damages Sought | Settlement |
|---|---|---|---|
| Legal Proceedings And Environmental Exposures | $170M | — | — |
| Legal Reserves | $165M | — | — |